Literature DB >> 25367745

Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX.

Zachary Reese1, Shiven Patel, David D Stenehjem, Ignacio Garrido-Laguna.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25367745     DOI: 10.1007/s12029-014-9662-3

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  22 in total

Review 1.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

2.  FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.

Authors:  Jason E Faris; Lawrence S Blaszkowsky; Shaunagh McDermott; Alexander R Guimaraes; Jackie Szymonifka; Mai Anh Huynh; Cristina R Ferrone; Jennifer A Wargo; Jill N Allen; Lauren E Dias; Eunice L Kwak; Keith D Lillemoe; Sarah P Thayer; Janet E Murphy; Andrew X Zhu; Dushyant V Sahani; Jennifer Y Wo; Jeffrey W Clark; Carlos Fernandez-del Castillo; David P Ryan; Theodore S Hong
Journal:  Oncologist       Date:  2013-05-08

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

4.  Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX.

Authors:  Renata D Peixoto; Maria Ho; Daniel J Renouf; Howard J Lim; Sharlene Gill; Jenny Y Ruan; Winson Y Cheung
Journal:  Am J Clin Oncol       Date:  2017-10       Impact factor: 2.339

Review 5.  FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity.

Authors:  Krishna S Gunturu; Xiaopan Yao; Xiangyu Cong; Jaykumar R Thumar; Howard S Hochster; Stacey M Stein; Jill Lacy
Journal:  Med Oncol       Date:  2012-12-28       Impact factor: 3.064

6.  Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.

Authors:  Philip A Philip; Jacqueline Benedetti; Christopher L Corless; Ralph Wong; Eileen M O'Reilly; Patrick J Flynn; Kendrith M Rowland; James N Atkins; Barry C Mirtsching; Saul E Rivkin; Alok A Khorana; Bryan Goldman; Cecilia M Fenoglio-Preiser; James L Abbruzzese; Charles D Blanke
Journal:  J Clin Oncol       Date:  2010-07-06       Impact factor: 44.544

7.  Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.

Authors:  Gilda da Cunha Santos; Neesha Dhani; Dongsheng Tu; Kayu Chin; Olga Ludkovski; Suzanne Kamel-Reid; Jeremy Squire; Wendy Parulekar; Malcolm J Moore; Ming Sound Tsao
Journal:  Cancer       Date:  2010-09-07       Impact factor: 6.860

8.  Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

Authors:  E Van Cutsem; H van de Velde; P Karasek; H Oettle; W L Vervenne; A Szawlowski; P Schoffski; S Post; C Verslype; H Neumann; H Safran; Y Humblet; J Perez Ruixo; Y Ma; D Von Hoff
Journal:  J Clin Oncol       Date:  2004-04-15       Impact factor: 44.544

9.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

10.  A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.

Authors:  S R Bramhall; J Schulz; J Nemunaitis; P D Brown; M Baillet; J A C Buckels
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.